Gimme Care Review
Best for: affordable compounded GLP-1 with nationwide coverage and microdose options
Gimme Care offers compounded semaglutide ($130–$160/mo) and compounded tirzepatide ($163–$199/mo) including microdose options. LegitScript verified. Available in all 50 states + DC. No membership fees.
High confidence · Last verified 2026-04-10 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Gimme Care offers the broadest state availability and easiest access.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded Semaglutide (3-mo) | compounded | $130 |
| Compounded Semaglutide (1-mo) | compounded | $160 |
| Compounded Tirzepatide (3-mo) | compounded | $163 |
| Compounded Tirzepatide (1-mo) | compounded | $199 |
✓ Pros
- •All 50 states + DC coverage — broadest availability in the dataset
- •LegitScript verified
- •Both semaglutide and tirzepatide in compounded formats
- •Microdose options available for both drugs
- •No membership fees — price includes medication, physician, support, shipping, and supplies
- •Multi-month discount: semaglutide $130/mo on 3-month plan
✗ Cons
- •Five states require video/audio visits (KS, LA, MS, NM, WV)
- •Compounded only — no brand-name options
- •Also offers anti-aging treatments (NAD+, Sermorelin, Glutathione)
Ready to start with Gimme Care?
Starting at $130/month. See current pricing and start your free consultation.
Sources & methodology
Our Gimme Care review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Gimme Care
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with Gimme Care?
Starting at $130/month. See current pricing and start your free consultation.